San Francisco-based CRO Vial is linking with Egnyte to use the company’s cloud-focused life sciences platform to make clinical trials faster and more efficient.
As part of the deal, Vial gets to integrate Egnyte’s eTMF (electronic trial master file) offering into its own technology. Vial combines trial onboarding, patient enrollment, site communication and data collection processes into one connected system, while Egnyte is able to automatically classify and manage metadata through document type identification, Vial explained in a Feb. 9 release.
"Egnyte's eTMF solution is designed to meet the needs of the growing class of emerging and midsize biosciences companies," Ronen Vengosh, Egnyte’s vice president of life sciences, said in the release. "By capitalizing on the simplicity and ease of the Egnyte for Life Sciences platform, Vial will be able to alleviate the data management burdens associated with trial studies, so clinical teams can focus on their core mission—getting safe and effective treatments to market quickly."
Vial launched the latest version of its clinical trial management system in August last year. Dubbed VialConnect, the platform is designed to facilitate faster patient screening and recruitment by allowing clinics to identify prospective trial participants.
The same year also saw Vial launch its oncology, dermatology and ophthalmology CRO units.